Literature DB >> 7843413

Full-length and short forms of utrophin, the dystrophin-related protein.

T M Nguyen1, T R Helliwell, C Simmons, S J Winder, J Kendrick-Jones, K E Davies, G E Morris.   

Abstract

All previous studies of the localization of utrophin (the dystrophin-related protein) in muscle and other tissues have been performed only with antibodies against the C-terminal region of the protein. Since several short forms of dystrophin, the apo-dystrophins, are produced from the 3' end of the dystrophin gene, there is a possibility that similar short forms of utrophin exist and that these could be responsible for some of the many different localizations of 'utrophin' in muscle. We have produced a new panel of 15 mAbs against the N-terminal region of utrophin and we have used it together with mAbs against the C-terminal region to show that full-length utrophin is present at neuromuscular junctions, in nerves, blood vessels and capillaries in normal muscle and in the sarcolemma of patients with muscular dystrophy and dermatomyositis. However, two of the 15 mAbs also recognised rat/mouse utrophin and both of these detected an additional 62 kDa protein on Western blots of rat C6 glioma cells. This potential 62 kDa 'apo-utrophin' was not detected in human cerebral cortex, in rat Schwannoma cells nor in any of the non-nerve cells and tissues tested.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7843413     DOI: 10.1016/0014-5793(94)01441-3

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  9 in total

1.  Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice.

Authors:  Alison R Amenta; Atilgan Yilmaz; Sasha Bogdanovich; Beth A McKechnie; Mehrdad Abedi; Tejvir S Khurana; Justin R Fallon
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

2.  Disruption of the utrophin-actin interaction by monoclonal antibodies and prediction of an actin-binding surface of utrophin.

Authors:  G E Morris; T M Nguyen; T N Nguyen; A Pereboev; J Kendrick-Jones; S J Winder
Journal:  Biochem J       Date:  1999-01-01       Impact factor: 3.857

Review 3.  The membrane-cytoskeleton interface: the role of dystrophin and utrophin.

Authors:  S J Winder
Journal:  J Muscle Res Cell Motil       Date:  1997-12       Impact factor: 2.698

4.  Dystroglycan receptor is involved in integrin activation in intestinal epithelia.

Authors:  Adel Driss; Laetitia Charrier; Yutao Yan; Vivienne Nduati; Shanthi Sitaraman; Didier Merlin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-12-15       Impact factor: 4.052

Review 5.  Therapeutics for Duchenne muscular dystrophy: current approaches and future directions.

Authors:  Sasha Bogdanovich; Kelly J Perkins; Thomas O B Krag; Tejvir S Khurana
Journal:  J Mol Med (Berl)       Date:  2003-12-12       Impact factor: 4.599

6.  Re-evaluation of the distributions of dystrophin and utrophin in sciatic nerve.

Authors:  E Fabbrizio; J Latouche; F Rivier; G Hugon; D Mornet
Journal:  Biochem J       Date:  1995-11-15       Impact factor: 3.857

7.  Tissue expression and actin binding of a novel N-terminal utrophin isoform.

Authors:  Richard A Zuellig; Beat C Bornhauser; Ralf Amstutz; Bruno Constantin; Marcus C Schaub
Journal:  J Biomed Biotechnol       Date:  2011-11-14

8.  Postsynaptic abnormalities at the neuromuscular junctions of utrophin-deficient mice.

Authors:  A E Deconinck; A C Potter; J M Tinsley; S J Wood; R Vater; C Young; L Metzinger; A Vincent; C R Slater; K E Davies
Journal:  J Cell Biol       Date:  1997-02-24       Impact factor: 10.539

9.  Brain dystrophin-glycoprotein complex: persistent expression of beta-dystroglycan, impaired oligomerization of Dp71 and up-regulation of utrophins in animal models of muscular dystrophy.

Authors:  K Culligan; L Glover; P Dowling; K Ohlendieck
Journal:  BMC Cell Biol       Date:  2001-02-02       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.